New Aspirin Compound Reduces Inflammation in Human Cells
Author Information
Author(s): Catriona M Turnbull, Paolo Marcarino, Tara A Sheldrake, Loretta Lazzarato, Clara Cena, Roberta Fruttero, Alberto Gasco, Sarah Fox, Ian L Megson, Adriano G Rossi
Primary Institution: Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh
Hypothesis
Do novel NO-aspirin hybrids have anti-inflammatory properties in LPS-activated human monocytes and macrophages?
Conclusion
The furoxan-aspirin compound B8 significantly reduces TNFα release from both monocytes and macrophages, likely through inhibition of NF-κB activation.
Supporting Evidence
- B8 reduced TNFα release from LPS-treated macrophages to 36 ± 10% of the control.
- B8 and B16 significantly inhibited monocyte TNFα release to 28 ± 5% and 49 ± 9% of control, respectively.
- The effect of B8 was equivalent to that of dexamethasone.
- None of the treatments caused significant cell lysis.
Takeaway
A new type of aspirin can help reduce inflammation in certain immune cells, which might be useful for treating diseases like arthritis.
Methodology
Human blood was collected, mononuclear cells were isolated, and macrophages were treated with various compounds to assess TNFα release and NF-κB activation.
Potential Biases
Potential bias in the selection of compounds and concentrations used for testing.
Limitations
The study may not fully represent in vivo conditions and the effects of the compounds may vary in different biological contexts.
Participant Demographics
Non-smokers aged 20-45 years.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website